Peripheral modulation of antidepressant targets MAO-B and GABAAR by harmol induces mitohormesis and delays aging in preclinical models
Luis Filipe Costa-Machado,Esther Garcia-Dominguez,Rebecca L McIntyre,Jose Luis Lopez-Aceituno,Álvaro Ballesteros-Gonzalez,Andrea Tapia-Gonzalez,David Fabregat-Safont,Tobias Eisenberg,Jesús Gomez,Adrian Plaza,Aranzazu Sierra-Ramirez,Manuel Perez,David Villanueva-Bermejo,Tiziana Fornari,María Isabel Loza,Gonzalo Herradon,Sebastian J Hofer,Christoph Magnes,Frank Madeo,Janet S Duerr,Oscar J Pozo,Maximo-Ibo Galindo,Isabel Del Pino,Riekelt H Houtkooper,Diego Megias,Jose Viña,Mari Carmen Gomez-Cabrera,Pablo J Fernandez-Marcos
DOI: https://doi.org/10.1038/s41467-023-38410-y
2023-05-15
Abstract:Reversible and sub-lethal stresses to the mitochondria elicit a program of compensatory responses that ultimately improve mitochondrial function, a conserved anti-aging mechanism termed mitohormesis. Here, we show that harmol, a member of the beta-carbolines family with anti-depressant properties, improves mitochondrial function and metabolic parameters, and extends healthspan. Treatment with harmol induces a transient mitochondrial depolarization, a strong mitophagy response, and the AMPK compensatory pathway both in cultured C2C12 myotubes and in male mouse liver, brown adipose tissue and muscle, even though harmol crosses poorly the blood-brain barrier. Mechanistically, simultaneous modulation of the targets of harmol monoamine-oxidase B and GABA-A receptor reproduces harmol-induced mitochondrial improvements. Diet-induced pre-diabetic male mice improve their glucose tolerance, liver steatosis and insulin sensitivity after treatment with harmol. Harmol or a combination of monoamine oxidase B and GABA-A receptor modulators extend the lifespan of hermaphrodite Caenorhabditis elegans or female Drosophila melanogaster. Finally, two-year-old male and female mice treated with harmol exhibit delayed frailty onset with improved glycemia, exercise performance and strength. Our results reveal that peripheral targeting of monoamine oxidase B and GABA-A receptor, common antidepressant targets, extends healthspan through mitohormesis.